Please ensure Javascript is enabled for purposes of website accessibility

HEXO Wins a New Pair of Licenses

By Eric Volkman - Oct 29, 2019 at 10:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The licenses will allow the company to sell "Cannabis 2.0" products from its home in Quebec and conduct R&D activities in an Ontario facility.

Marijuana company HEXO (HEXO -2.82%) is reporting two closely related pieces of good news. The company announced on Monday that it had received a pair of licenses from cannabis industry regulator Health Canada for facilities in different parts of the sprawling country.

The first is a sales license for its campus located in its home city of Gatineau, Quebec (which incidentally is located close to the nation's capital of Ottawa, Ontario). This permit will allow HEXO to sell derivative products such as cannabis-infused drinks and extracts from the facility. The second is a research-and-development license granted to the company's Centre of Excellence facility in the small Ontario municipality of Belleville.

Gloved hand holding marijuana leaf in front of Canadian flag.

Image source: Getty Images.

Both licenses will bolster HEXO's activities under the so-called Cannabis 2.0 legalization in Canada. This initiative, enacted in mid-October, sanctions the licensed sale of derivative products in the country. It came into force one year after Canada legalized recreational cannabis.

In the press release announcing the obtaining of the licenses, HEXO seemed more enthusiastic about the R&D one for the Belleville facility. It wrote that this permit "will allow us to take our innovation work to the next level, with testing on derivative products, including taste testing. Consumers have high expectations for their packaged goods experiences, and cannabis will be no different."

The two licenses represent HEXO's first initial step toward official sales of derivative products. Investors have been eager for Canadian companies to enter this space, as derivative products are generally higher margin than traditional cannabis flower offerings. They are also popular with consumers who, for a variety of reasons, don't wish to consume cannabis by smoking.

Profitability remains a subject of great concern for marijuana stock investors. Due partially to a host of challenging external factors such as supply issues and licensing delays, Canadian operators, in particular, have frequently posted bottom-line losses. The rollout of derivative products in the country promises to give those companies a better shot at landing in the black.

Although HEXO's licensing news is positive, it comes on the heels of several troubling developments for the company. Last week, it announced a set of job cuts and delayed the release of its Q4 and full-year fiscal 2019 results. It also withdrew its previously issued guidance for fiscal 2020.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

HEXO Stock Quote
$0.25 (-2.82%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.